INTRODUCTION: [(68)Ga-DOTA-D-Phe1-Tyr3]octreotide ([(68)Ga]Ga-DOTA-TOC) is a somatostatin analogue largely used in PET/CT applications for the detection of gastroenteropancreatic neuroendocrine tumors (GEP-NET). Initially, it was obtained using a (68)Ge/(68)Ga generator. The increasing cost of good manufacturing practice-compliant generators has led to the need to find alternative ways of producing Gallium-68 ((68)Ga). The aim of this work is to show the production optimization of [(68)Ga]Ga-DOTA-TOC via cyclotron, derived from three years of experience. METHODS: The production of [(68)Ga]GaCl(3) via the (68)Zn(p,n)(68)Ga reaction was optimized using a PETtrace 800 cyclotron (equipped with ZnO liquid target) and the synthesis of [(68)Ga]Ga- DOTA-TOC was performed by FASTlab2 developer system according to the Guidelines on Good Radiopharmacy Practice (cGRPP). Quality control process was validated according to the current specific monograph (2482) of the European Pharmacopoeia (Ph. Eur.). RESULTS: [(68)Ga]Ga-DOTA-TOC was produced in 40 minutes; ten validation batches met the quality criteria expected by the Ph. Eur. The synthesis process has involved many issues due to the use of acidic reagents and related corrosion of some components of cyclotron and developer system, resulting in 12.2% failed syntheses and a target breakdown after 11 months. DISCUSSION: The main issues, their causes and the strategies used to solve them are reported in the troubleshooting section: thanks to these strategies, the number of failed syntheses has decreased, and today, we have achieved a 0% failure rate. CONCLUSION: Liquid target production of [(68)Ga]Ga-DOTA-TOC, once consolidated, instead of (68)Ge/(68)Ga generator has many advantages.
[(68)Ga]Ga-DOTA-TOC Synthesis by a Cassette Developer System with [(68)Ga]GaCl(3) from Cyclotron using Liquid Target: An Italian Experience.
阅读:8
作者:Cossandi Michela, Statuto Massimo, Biasiotto Giorgio, Vigano Gian Luca, Camoni Luca, Migliorati Elena, Rodella Carlo, Saiani Federica, Spiazzi Luigi, Bertagna Francesco
| 期刊: | Current Radiopharmaceuticals | 影响因子: | 1.200 |
| 时间: | 2025 | 起止号: | 2025;18(4):302-317 |
| doi: | 10.2174/0118744710379515250506045145 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
